cilostazol has been researched along with Kidney Diseases in 5 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD." | 3.83 | Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. ( Aoyama, T; Ishii, H; Ito, Y; Kamoi, D; Kumada, Y; Murohara, T; Sakakibara, T; Suzuki, S; Takahashi, H; Tanaka, A; Umemoto, N, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hafez, HM | 1 |
| Ibrahim, MA | 1 |
| Zedan, MZ | 1 |
| Hassan, M | 1 |
| Hassanein, H | 1 |
| Ishii, H | 1 |
| Aoyama, T | 1 |
| Takahashi, H | 1 |
| Kumada, Y | 1 |
| Kamoi, D | 1 |
| Sakakibara, T | 1 |
| Umemoto, N | 1 |
| Suzuki, S | 1 |
| Tanaka, A | 1 |
| Ito, Y | 1 |
| Murohara, T | 1 |
| He, P | 1 |
| Kawamura, H | 1 |
| Takemoto, M | 1 |
| Maezawa, Y | 1 |
| Ishikawa, T | 1 |
| Ishibashi, R | 1 |
| Sakamoto, K | 1 |
| Shoji, M | 1 |
| Hattori, A | 1 |
| Yamaga, M | 1 |
| Ide, S | 1 |
| Ide, K | 1 |
| Hayashi, A | 1 |
| Tokuyama, H | 1 |
| Kobayashi, K | 1 |
| Yokote, K | 1 |
| Woo, JS | 1 |
| Kim, W | 1 |
| Lee, SR | 1 |
| Jung, KH | 1 |
| Kim, WS | 1 |
| Lew, JH | 1 |
| Lee, TW | 1 |
| Lim, CK | 1 |
| Choi, YH | 1 |
| Suh, SH | 1 |
| Choi, JS | 1 |
| Kim, CS | 1 |
| Sim, DS | 1 |
| Bae, EH | 1 |
| Lim, SY | 1 |
| Ma, SK | 1 |
| Jeong, MH | 1 |
| Kim, SW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for cilostazol and Kidney Diseases
| Article | Year |
|---|---|
Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney di
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cilostazol; Clopidogrel; Coronary Arte | 2011 |
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Comb | 2012 |
3 other studies available for cilostazol and Kidney Diseases
| Article | Year |
|---|---|
Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2/HO-1/NQO-1 signaling pathway.
Topics: Animals; Antioxidants; Cilostazol; Cytoprotection; Disease Models, Animal; Heme Oxygenase (Decyclizi | 2019 |
Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
Topics: Aged; Cilostazol; Disease-Free Survival; Female; Humans; Kidney Diseases; Male; Middle Aged; Periphe | 2016 |
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilos | 2017 |